Platelet inhibition with cangrelor in patients undergoing PCI. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman NS, et al. Cangrelor: clinical data, contemporary use, and future perspectives. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient‐level data. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. doi: 10.1177/0091270009344986īhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. Looking for information on the anime To Heart 2 Find out more with MyAnimeList, the worlds most active online anime and manga community and database. ![]() These findings highlight opportunities for optimization of cangrelor dosing, infusion duration, and transition of care from the catheterization laboratory to the ward setting.Īntiplatelet cangrelor myocardial infarction.Īkers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Conclusions This multicenter registry demonstrated interhospital variability in how cangrelor was administered and transitioned to an oral P2Y 12 inhibitor. Only 27.3% were dosed with cangrelor and transitioned to an oral P2Y 12 inhibitor in a fashion consistent with the pivotal trials and US Food and Drug Administration label. Cangrelor was infused for a median of 121 (76-196) minutes and 38.3% received an infusion for 1-hour gap between cangrelor cessation and oral P2Y 12 inhibitor initiation this was highest among those transitioned to clopidogrel (56.6% versus 34.5% prasugrel versus 10.8% ticagrelor P<0.001). Of patients receiving cangrelor in both phases (n=819), 3.3% received either the bolus or infusion only. In phase 1, cangrelor use varied across hospitals (overall, 50.4% ). In phase 2, data were collected in a 2:1 (cangrelor-: non-cangrelor-treated) ratio of patients with myocardial infarction (n=873). Our medical volunteers save lives, empower doctors, and strengthen communities through their teaching, training, and mentoring. ![]() Already suffering a fatal blow, her heart almost. In phase 1, data were collected on consecutive patients with myocardial infarction (n=482) treated with any P2Y 12 inhibitor to understand cangrelor use by hospital. On the day her father is diagnosed with Alzheimers, Lin Zhao Xis (Zhang Zi Feng) heart is broken. Methods and Results The CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry is a multicenter, retrospective observational study of platelet inhibition strategies for patients with myocardial infarction undergoing percutaneous coronary intervention. This study was performed to examine cangrelor use and transition to oral P2Y 12 inhibitors in routine clinical practice. Background In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention-related ischemic complications without increasing major bleeding.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |